Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03604198 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 44 → 48 locations Eligibility criteria expanded, about 6 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 6 words
  2. Trial sites reduced: 48 → 44 locationsv47
  3. Eligibility criteria shortened, about 19 wordsv46 See this version in full on ClinicalTrials.gov ↗
  4. Re-verified, no change to tracked fieldsv45
  5. Primary and study completion dates: Dec 2025 to Dec 2026v44
Show 42 earlier versionsHide 42 earlier versions
  1. Re-verified, no change to tracked fieldsv43
  2. Study sites: 49 to 48v42
  3. Study sites: 50 to 49v41
  4. Study sites: 52 to 50v40
  5. Trial status: Enrolling by Invitation to Active, Not Recruiting Enrollment target: estimated 75 to confirmed 125v39 Show 1 more changeShow less
    • Enrollment target: estimated 75 to confirmed 125
  6. Study sites: 50 to 52v38
  7. Re-verified, no change to tracked fieldsv37
  8. Primary and study completion dates: Dec 2024 to Dec 2025v36
  9. Study sites: 49 to 50v35
  10. Re-verified, no change to tracked fieldsv34
  11. Study sites: 47 to 49v33
  12. Study sites: 48 to 47v32
  13. Study sites: 47 to 48v31
  14. Study sites: 46 to 47v30
  15. Study sites: 45 to 46v29
  16. Study sites revised (45)v28 See this version in full on ClinicalTrials.gov ↗
  17. Study sites: 44 to 45v27
  18. Study sites: 43 to 44v26
  19. Primary and study completion dates: Dec 2022 to Dec 2024 Study sites: 41 to 43v25 Show 1 more changeShow less
    • Study sites: 41 to 43
  20. Study sites: 39 to 41v24
  21. Study sites: 38 to 39v23
  22. Study sites: 39 to 38v22
  23. Study sites: 37 to 39v21
  24. Study sites: 34 to 37v20
  25. Study sites: 31 to 34v19
  26. Study sites: 30 to 31v18
  27. Study sites: 29 to 30v17
  28. Study sites: 28 to 29v16
  29. Study sites: 26 to 28v15
  30. Study sites: 23 to 26v14
  31. Study sites: 21 to 23v13
  32. Study sites: 19 to 21v12
  33. Primary and study completion dates: Jul 2021 to Dec 2022v11
  34. Study sites: 18 to 19v10
  35. Re-verified, no change to tracked fieldsv9
  36. Study sites: 15 to 18v8
  37. Study sites: 14 to 15v7
  38. Study sites: 13 to 14v6
  39. Study sites: 11 to 13v5
  40. Study sites: 4 to 11v4
  41. Re-verified, no change to tracked fieldsv3
  42. Primary endpoints: 2 to 1 Trial status: Recruiting to Enrolling by Invitation · Study sites: 2 to 4 · Secondary endpoints shortened, about 51 words · 1 morev2 Show 4 more changesShow less
    • Trial status: Recruiting to Enrolling by Invitation
    • Study sites: 2 to 4
    • Secondary endpoints shortened, about 51 words
    • Study title shortened, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.
Trial Details
NCT Number NCT03604198
Lead Sponsor Corcept Therapeutics
Conditions Cushing Syndrome
Enrollment 125 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov